Cross-Sectional Analysis of Immunohistochemical Expression of Mismatch Repair  Proteins in Prostate Cancer

Muhammad Atif Khalil; Nadeem  Zafar; Hassan  Tariq; Wajahat Ahmed  Khan; Moniba  Zafar; Muhammad Owais  Qurni; Siyab  Ahmed

doi:10.51253/pafmj.v75i4.10310

Authors

Muhammad Atif Khalil Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Nadeem Zafar Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Hassan Tariq Department of Histopathology, Combined Military Hospital Malir/National University of Medical Sciences (NUMS) Pakistan
Wajahat Ahmed Khan Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Moniba Zafar Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Owais Qurni Department of Histopathology, Combined Military Hospital Multan/National University of Medical Sciences (NUMS) Pakistan
Siyab Ahmed Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i4.10310

Keywords:

Immunohistochemical Expression, Microsatellite Instability (MSI), Mismatch Repair (MMR) Deficiency, MSH-2, MSH-6, MLH-1, PMS-2, Prostatic Carcinoma

Abstract

Objective: To determine the immunohistochemistry-based frequency of mismatch repair protein (MSH-2, MSH-6, MLH-1 & PMS-2) deficiency in prostate cancer.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, from Jan 2021 to Jul 2022.

Methodology: The characteristics and clinical data of 82 prostatic cancer patients who had transurethral resection of the prostate and surgical resections were examined. MLH-1, MSH-2, PMS-2, and MSH-6 antibodies were utilized during immune-histochemical staining. The status of each patient's mismatch repair deficit was established once the results were assessed.

Results: In the study, mean age of presentation was 70.90±8.36 years. Most common histological type was acinar adenocarcinoma, 67(81.70%). Out of 82 patients with prostatic carcinoma, 17(20.73%) patients had lost their immunohistochemistry staining for MMR proteins. Nonetheless, no mismatch repair deficit was found in the 65(79.27%) remaining instances. One patient had a simultaneous loss of all four antibodies, two had loss of MLH-1, three had loss of MSH-2, eleven had loss of PMS-2, and twelve had loss of MSH-6.

Conclusion: The frequency of mismatch repair deficiency in our community's prostate cancer patients was reported to be 34.1%, which may be utilized as a base for genetic testing to track the effectiveness of treatment and forecast the overall survival rate for patients with prostate cancer. Studies are also needed to explain the MMR protein’s genetic role in cancer formation, together with the signaling pathway.

Downloads

Download data is not yet available.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34. https://doi:10.3322/caac.21551

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.

https://doi:10.3322/caac.21492

3. Bugoye FC, Torrorey-Sawe R, Biegon R, Dharsee N, Mafumiko FMS, Patel K, et al. Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer. Front Genet 2023; 14: 1231536. https://doi:10.3389/fgene.2023.1231536

4. Mahmood S, Qasmi G, Ahmed A, Kokab F, Zahid MF, Afridi MI, et al. Lifestyle factors associated with the risk of prostate cancer among Pakistani men. J Ayub Med Coll Abbottabad 2012; 24(2): 111-115.

5. VVan den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019; 75(6): 967-987. https://doi:10.1016/j.eururo.2018.10.011

6. Ferro M, de Cobelli O, Vartolomei MD, Lucarelli G, Crocetto F, Barone B, et al. Prostate Cancer Radiogenomics-From Imaging to Molecular Characterization. Int J Mol Sci 2021; 22(18): 9971.

https://doi:10.3390/ijms22189971

7. Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 2014; 5: 4988.

https://doi:10.1038/ncomms5988

8. Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 2013; 31(14): 1713-1718.

https://doi:10.1200/JCO.2012.44.1238

9. Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest 2018; 128(10): 4441-4453.

https://doi.org/10.1172/jci121924

10. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481(7381): 287-294.

https://doi:10.1038/nature10760

11. Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, et al. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. Carcinogenesis 2017; 38(1): 19-27.

https://doi:10.1093/carcin/bgw116

12. Javeed S, Chughtai A, Zafar G, Khalid F, Batool A, Chughtai AS. An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma. Cureus 2022; 14(7): e27448.

https://doi:10.7759/cureus.27448

13. Sharma M, Yang Z, Miyamoto H. Loss of DNA mismatch repair proteins in prostate cancer. Medicine 2020; 99(19): e20124. https://doi:10.1097/MD.0000000000020124

14. Albero-González R, Hernández-Llodrà S, Juanpere N, Lorenzo M, Lloret A, Segalés L, et al. Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status. Virchows Arch 2019; 475(2): 223-231.

https://doi:10.1007/s00428-019-02591-z

15. Goldberg KB, Blumenthal GM, Pazdur R. The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory Environment. Cancer J 2018;24(3):131-135. https://doi:10.1097/PPO.0000000000000316.

16. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372(26): 2509-2520.

https://doi:10.1056/NEJMoa1500596

17. Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother 2019; 15(5): 1111-1122.

https://doi:10.1080/21645515.2019.1571892

18. Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 2018; 11(5): 475-486.

https://doi:10.1080/17512433.2018.1464388